Axial Spondyloarthritis (axSpA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Axial Spondyloarthritis Emerging Therapy and TPP Insights

Thelansis’s “Axial Spondyloarthritis (axSpA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Axial Spondyloarthritis Overview

Axial spondyloarthritis is a chronic immune-mediated inflammatory rheumatic disease affecting the sacroiliac joints and spine, causing inflammatory back pain, stiffness, impaired function, and, in some patients, progressive structural damage and spinal ankylosis. The treatment landscape has evolved from NSAIDs and other anti-inflammatory measures to targeted therapies, with TNF and IL-17 inhibitors established as major biologic options and JAK inhibitors expanding the oral treatment landscape. Despite these advances, substantial unmet needs remain, including delayed diagnosis, incomplete responses, treatment intolerance, and uncertainty over whether current therapies can reliably prevent new bone formation and long-term structural progression. This has driven development toward increasingly selective mechanisms. Bimekizumab, which simultaneously inhibits IL-17A and IL-17F, is already approved for both non-radiographic axSpA and ankylosing spondylitis, while emerging approaches such as selective ERAP1 inhibition are exploring entirely new biology. For stakeholders, axSpA represents an important therapeutic frontier where the next advance will depend not only on controlling inflammation, but on achieving durable disease control and more meaningful protection against structural progression.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)